|Bid||141.37 x 800|
|Ask||142.00 x 1000|
|Day's range||133.34 - 143.99|
|52-week range||31.71 - 189.26|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Moderna to present at the 20th Annual Needham Virtual Healthcare Conference.
Moderna highlights publication of antibody persistence data of its COVID-19 Vaccine out to 6 months in The New England Journal of Medicine.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the expansion of their strategic collaboration to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs in Moderna’s pipeline, at Catalent’s biologics facility in Bloomington, Indiana.